ROBOSENSE
23.12.2021 15:02:07 CET | Business Wire | Press release
RoboSense announced a strategic partnership with Horizon Robotics, a global pioneer in edge AI computing platforms. The two partners will mobilize their respective technological capacity and mass production experience to roll out in-depth cooperation focusing on advanced driver assistance systems (ADAS), autonomous driving, robotics, new intelligent transportation infrastructure and other applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211223005234/en/
Leveraging its leading smart LiDAR software and hardware technologies, RoboSense will join hands with Horizon Robotics to promote the large-scale commercialization of all segments of intelligent connected vehicle.
According to the partnership agreement, based on RoboSense’s second generation smart solid-state LiDAR RS-LiDAR-M1 (hereinafter referred to as "M1") and Horizon Robotics’ Journey 3 and Journey 5 automotive smart chips, the two companies will collaborate on the development and adaptation of integrated perception solutions for high-level autonomous driving pre-installed mass production. In the future, the partners will mobilize their respective advantageous industry resources to jointly promote the all-round standardized implementation of the domestic intelligent connected transportation industry.
Dr. Chunxin Qiu, founder and CEO of RoboSense:
" This strategic partnership will form a greater joint force and empower the two companies to create more visionary intelligent driving product solutions for the industry, to jointly build a prosperous ecology of the vehicle intelligence industry and advance the development of the intelligent connected transportation industry. "
Dr. Kai Yu, founder and CEO of Horizon Robotics:
" Through this strategic partnership, the two companies will fully complement each other with respective advantageous resources, jointly explore cutting-edge technologies and promote the mass production and large-scale implementation of pioneering intelligent driving solutions of the industry, leveraging technological innovation to build a safer and better smart mobility experience for the future. "
RoboSense is currently the only company in China to realize the automotive-grade domestic mass production of pre-installed LiDAR. Its second generation smart solid-state LiDAR, M1, has obtained pre-installed fixed-point project orders from multiple brands including GAC AION, WM Motor, ZEEKR, Lotus Cars, Inceptio and Zhito, covering models including passenger cars and commercial vehicles.
Horizon Robotics is a global leader in edge AI computing platforms based on the forward-looking concept of software and hardware integration As the only company in China to realize the automotive-grade domestic mass production of pre-installed AI chips, Horizon Robotics has reached intended partnership on priority mass production delivery with multiple car manufacturers including SAIC Motor, GWM, JAC Group, Changan Auto and BYD.
RoboSense and Horizon Robotics have a profound partnership history. The two companies announced intended partnership as early as 2019, and have been discussing and exploring innovations and integration solutions of vehicle intelligence technology, laying a solid foundation for the implementation of long-term and stable partnership achievements in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005234/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release
Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release
Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom